Please login to the form below

bipolar disorder

This page shows the latest bipolar disorder news and features for those working in and with pharma, biotech and healthcare.

Alkermes’ new antipsychotic clears FDA advisory committee hurdle

Alkermes’ experimental antipsychotic for schizophrenia and bipolar I disorder ALKS 3831 has cleared an US Food and Drug Administration (FDA) expert advisory committee review. ... and bipolar I disorder,” said Craig Hopkinson, chief medical officer

Latest news

Sanofi faces manslaughter allegations in France over Depakine deaths

Depakine has been marketed by Sanofi since 1967 as an anti-epileptic and bipolar disorder treatment, and has since been associated with foetus malformation and neurodevelopmental disorders including autism and spina
Botox strength bolsters Allergan ahead of AbbVie takeover

The dopamine D2, D3 receptor partial agonist for schizophrenia and bipolar disorder could top the $1bn blockbuster threshold, well ahead of analyst forecast of around half that amount at peak just ... A new approval in bipolar depression has contributed
Sanofi indicted in France over epilepsy drug birth defects

Despite its maturity, the drug has been one of Sanofi’s reliable mid-size products, bringing in around 450m in sales from use in epilepsy and bipolar disorder in 2018.
Troubled Alkermes eyes November OK for new antipsychotic

Review begins for potential schizophrenia and bipolar I disorder drug. The FDA has started its review of Alkermes’ experimental antipsychotic for schizophrenia and bipolar I disorder – ALKS 3831 – setting up a ... Olanzapine is an effective and well
AstraZeneca divests Seroquel rights to focus on key therapy areas

Second divestment to Germany-based Cheplapharm this year. AstraZeneca has sold the commercial rights to schizophrenia and bipolar disorder drugs Seroquel and Seroquel XR to Cheplapharm. .

More from news
Approximately 7 fully matching, plus 87 partially matching documents found.

Latest Intelligence

Drug pricing in Ireland

As such, patients with coronary syndromes, multiple sclerosis, bipolar disorder and Hepatitis C were being denied access to effective treatments, while treatments for other diseases were also subject to restrictions.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

AN ADVOCACY Rx FOR PROGRESS IN MENTAL HEALTH

there’s an abundance of smart thinking on how to improve the lives of people who struggle with major depression, schizophrenia, bipolar disorder, and other serious conditions.

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

Senior Leadership Role – Medical Communications – North West: Highly Competitive Salary, Bonus &Benefits

Principal Medical Writer: Varies on experience

Senior Content Editor - Biotechnology: Salary TBC

FREELANCE Medical Writer, Senior Medical Writer, Principal Medic...: Highly Competitive Day Rate, Bonus &Benefits

Freelance Account Manager - Creative Healthcare Comms - Immediat...: Excellent Day Rate

Freelance Medical Writer - Creative Healthcare Comms - 2 month t...: Excellent Day Rate

Senior Account / Programme Manager - MedComms - Buckinghamshire: Highly Competitive Remuneration packages

Account Management: Competitive Salary Offered

PMHub

Add my company

ROAD

ROAD is a digital PR and communications consultancy specialising in promoting the innovators that shape our future health and wellbeing....

Latest intelligence

WHITE PAPER: Why do men die younger?: It’s a commonly accepted fact that women outlive men. Wherever you live, there’s a good chance that men will die on average eight years earlier than women. Is this an...
3 tips to show patient diversity in your clinical trial materials: Here are some useful tips to help get your hands on authentically diverse stock photos....
Virtual congresses: video thrilled the cardio tsar: Chris Ross explores the key learnings from a year of virtual congresses...